Avycaz Generic: When Will Generic Ceftazidime and Avibactam Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Avycaz Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2028 to 2029 A wide window Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the brand’s protection end? June 2032 The last of 7 listed patents Why sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Dr. Brian Staiger Explains
PharmD, BCPS · Clinical pharmacistGeneric ceftazidime and avibactam sodium is expected to be available between 2028 and 2029. None is for sale yet.
Why 2028 to 2029?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. We rate it probable: more likely than not, but it can still move.
If Avycaz’s protection runs to June 2032, how can a generic come sooner?
The 5 patents that run past the expected month, to June 2032 (8,835,455, 8,471,025, 8,969,566, 9,284,314 and 1 more), cover the product’s formulation and the active ingredient. A generic can still come sooner if a court rules a patent invalid or not infringed, or if the companies settle on an earlier date. Here, a settlement between the companies sets the date. Generic companies have been challenging Avycaz’s patents with the FDA since February 2024. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 2 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 44% less once two companies sold a generic. See the price pattern
What should I do now?
Keep taking Avycaz as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Avycaz by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Moderate 2 companies have filed, 2 first in line
- Brand sales
- $258M a yearBig seller
- FDA approved 2015 February 2015 FDA Orange Book
- Patents listed 7 last runs to June 2032 FDA Orange Book
- Medicare Part D spent $24.4M in 2025, for 1,391 people CMS Part D Spending by Drug
- Medicaid prescriptions 1,576 in the last four reported quarters, $5.6M CMS Medicaid drug utilization, to Q1 2026
Avycaz’s Road to a Generic
Avycaz has had the market to itself since the FDA approved it in February 2015 (Abbvie Inc). Its FDA protection (new patient population) runs to January 2027. Its 7 listed patents run to June 2032 (1 already expired). Generic companies have challenged its patents with the FDA since February 2024.
The first generic of Avycaz is expected between 2028 and 2029.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
Why a Generic Can Come Before June 2032
The last listed patent runs to June 2032; a court ruling or a settlement can bring a generic sooner. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Avycaz Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Avycaz’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 7,112,592 | The active ingredient; the product’s formulation; a way of using it (U-2508, U-2244, U-282, U-3818) | January 2026 | Expired |
| 7,612,087 | The product’s formulation | November 2026 | Active |
| 8,835,455 | The product’s formulation | October 2030 | Active |
| 8,471,025 | The active ingredient | August 2031 | Active |
| 8,969,566 | The active ingredient | June 2032 | Active |
| 9,284,314 | The active ingredient | June 2032 | Active |
| 9,695,122 | The active ingredient | June 2032 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New patient population NPP | Three years of protection for a newly approved group of patients. | January 2027 | Active |
Source: FDA Orange Book, application 206494. Patent numbers open the patent on Google Patents.
Patent Challenges to Avycaz
The first patent challenge to Avycaz reached the FDA in February 2024, from 2 companies on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Avycaz’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| For injection, 0.5 g/2 g per vial | February 2024 | 2 companies | No decision yet | Not yet | Not yet | June 2032 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Ceftazidime and Avibactam Sodium
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
2 companies have applied to the FDA to make generic ceftazidime and avibactam sodium.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. 2 of them were first in line, both filing on the first day any company did: they can share 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Avycaz’s patents with the FDA since February 2024: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic ceftazidime and avibactam sodium. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic ceftazidime and avibactam sodium for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Avycaz Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Avycaz, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Avycaz
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Avycaz, before manufacturer rebates.
- $5.4M
- January to March 2026, the latest CMS has posted
For 342 people, about $5,175 per prescription fill - $24.4M
- 2025, the whole year
For 1,391 people, about $4,473 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $5,361,632 | 342 | $5,175.32 |
| 2025 | $24,388,540 | 1,391 | $4,472.50 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Avycaz only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat a wide variety of bacterial infections. This product contains 2 different medications: ceftazidime and avibactam.
Medicaid Prescriptions by Quarter
1,576 prescriptions in the four quarters to Q1 2026, $5.6M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 295 | $1,284,689 |
| Q4 2025 | 419 | $1,557,639 |
| Q3 2025 | 499 | $1,429,437 |
| Q2 2025 | 363 | $1,301,480 |
| Q1 2025 | 475 | $1,442,933 |
Source: CMS Medicaid State Drug Utilization Data, over Avycaz’s own package codes.
Avycaz Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 0.5GM BASE;2GM/VIAL | Powder | Intravenous | February 2015 | Prescription reference product |
Source: FDA Orange Book, Abbvie Inc. Listed for sale today by Allergan, Inc. (FDA NDC Directory).
Avycaz NDC Codes and Packages
Each Avycaz package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 00456-2700-10 | CEFTAZIDIME 2 g/1 / AVIBACTAM SODIUM .5 g/1 powder, for solution | carton of 10 vials of 1 powder | Allergan, Inc. |
| 00456-2700-10 | CEFTAZIDIME 2 g/1 / AVIBACTAM SODIUM .5 g/1 powder, for solution | carton of 10 vials of 1 powder | Allergan, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Avycaz’s own FDA approval (NDA 206494) are listed, never a generic. Some codes belong to companies that repackage Avycaz: it is the same medicine in a different package.
What a Generic Avycaz Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Avycaz as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Avycaz”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Avycaz
Is there a generic for Avycaz right now?
No. As of October 9, 2026 no generic ceftazidime and avibactam sodium is listed for sale in the FDA NDC Directory.
When will Avycaz go generic?
2028 to 2029 is the expected window, and that is probable but not certain. The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. The last listed patent runs to June 2032; a court ruling or a settlement can bring a generic sooner.
Will generic ceftazidime and avibactam sodium be the same as Avycaz?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 2 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 44% less once two companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Avycaz?
Not yet. The FDA Orange Book lists no approved generic version of Avycaz.
When does the Avycaz patent expire?
The FDA Orange Book lists 7 patents for Avycaz; the last runs to June 2032. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2028 to 2029) weighs all of that.
Has anyone challenged the Avycaz patents?
Yes. The first patent challenge to Avycaz reached the FDA in February 2024, from 2 companies on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected 2028 to 2029 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- Cresemba IVIsavuconazonium Sulfate2026 to 2027
- Utibron NeohalerGlycopyrrolate and Indacaterol MaleateDuring 2028
- MyoviewTechnetium TC-99M Tetrofosmin Kit2029 to 2030
- IcotydeIcotrokinraDuring 2041
- Revtorpyk IVGedatolisibAugust 2042
- ZyclaraImiquimodTBD no date yet
About Avycaz
- Generic name ceftazidime and avibactam sodium
- How it is taken Into a vein (IV)
- Company Abbvie Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since February 2024 (FDA)
- More drugs Brand-name drugs starting with A
- Have a question? A pharmacist answers, free. Ask about Avycaz
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.